Cite
HARVARD Citation
Xu, B. et al. (n.d.). LBA6First China-manufactured trastuzumab biosimilar HLX02 global phase III trial met primary endpoint in breast cancer. Annals of oncology. p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Xu, B. et al. (n.d.). LBA6First China-manufactured trastuzumab biosimilar HLX02 global phase III trial met primary endpoint in breast cancer. Annals of oncology. p. . [Online].